H ypertension as a major cardiovascular risk factor continues to be a significant health challenge 1 and imparts an increased risk of cardiovascular and kidney diseases. 2, 3 Hypertension is determined by multiple factors, and during the past years, the immune system (mainly T cells) and inflammatory processes have emerged as key contributors to elevated blood pressure (BP) in several experimental animal and human models.
H ypertension as a major cardiovascular risk factor continues to be a significant health challenge 1 and imparts an increased risk of cardiovascular and kidney diseases. 2, 3 Hypertension is determined by multiple factors, and during the past years, the immune system (mainly T cells) and inflammatory processes have emerged as key contributors to elevated blood pressure (BP) in several experimental animal and human models. 4, 5 A shared pathophysiology with manifest cardiac disease is suggested. 3, 6 Nevertheless, there is also a substantial genetic heritability of 30% to 60% for hypertension. 7 Large-scale genome-wide association studies on hypertension or BP traits have been published. [8] [9] [10] Some of the identified genetic variants primarily associated with higher BP also confer an increased risk for coronary artery disease, consistent with a causal relationship of increased BP and coronary artery disease risk. 11, 12 However, the distinct genetic variants identified by genome-wide association studies to date exhibit small effect sizes and explain 3.5% of the BP variance. 10, 11, 13 Moreover, most genes near the identified genetic variants are not known to be functionally related to BP. 14 Global gene expression profiling offers novel possibilities for functional genomics, and possible effects of genetic variants on clinical phenotypes may be uncovered. Recent gene expression analyses for hypertension and BP traits identified gene expression signatures involved in multiple biological processes that contribute to BP regulation. [15] [16] [17] [18] [19] Here, we investigated (1) the global gene expression based on transcripts levels in relation to BP traits in a 2-stage meta-analysis of 4 population-based studies, (2) the relationship of changes in BP and transcript levels over time, and (3) the clinical application of candidate genes as BP-related biomarkers.
Material and Methods
A detailed description of the methods and the study samples is given in the online-only Data Supplement. All studies followed the recommendations of the Declaration of Helsinki, and study protocols were approved by the local ethics committees. Written informed consent was obtained from all study participants.
Study Workflow
The study workflow is outlined in Figure S1 in the online-only Data Supplement.
1. A discovery meta-analysis of global monocyte gene expression and BP traits (systolic BP [SBP] , diastolic BP [DBP] , and pulse pressure) was performed combining data from the population-based studies GHS (Gutenberg Health Study) 22 (n=1285) and MESA (Multi-Ethnic Study of Atherosclerosis) 23 (n=1264). Multiple testing was controlled by a false discovery rate approach implementing the Benjamin-Hochberg method. At this step, a false discovery rate threshold of 0.01 was used. ). Criteria were (1) evidence for statistical significance (P<0.05) in each study for at least 1 BP trait, and (2) consistent direction of effect in discovery and replication. To relate expression of candidate transcripts to BP changes, transcript levels were assessed in different settings: (1) a setting of longterm changes in BP for 5 years in GHS (n=1092), and (2) in the setting of a clinical trial to test the influence of BP-lowering medication by routinely used telmisartan/amlodipine and olmesartan on candidate transcript levels for 6 months (n=406).
To assess additional clinical implications of the findings, candidate transcript levels were linked to measures of subclinical cardiovascular disease (CVD), and the relation of protein levels encoded by BP-related candidate transcripts was determined for incident cardiovascular events in serum samples of the population-based Moli-Sani Study 26 (n=379) to test the applicability as circulating biomarkers.
Gene Expression Profiling Using Microarray Technology
In GHS, KORA F4, and SHIP-TREND, RNA was processed using the Illumina TotalPrep-96 RNA Amp Kit (Ambion, Darmstadt, Germany), and labeled cRNA was hybridized to the Illumina HumanHT-12 v3 Expression BeadChip as described previously.
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GHS 5-year follow-up samples were processed using the Illumina TotalPrep-96 RNA Amp Kit (Ambion), and labeled cRNA was hybridized to the IlluminaHT-12 v4 Expression BeadChips following manufactures recommendations. In MESA, the Illumina TotalPrep-96 RNA Amplification Kit (Ambion) and the Illumina HumanHT-12 v4 Expression BeadChip were used for gene expression profiling.
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Statistical Analyses
Identification of BP-Related Candidate Transcripts
The microarray data were pre-processed, normalized, log2-transformed, and quality controlled as described previously for GHS, KORA, SHIP-TREND, 27 and MESA. 28 Associations between mRNA levels and BP traits were estimated using linear regression models and adjusted for sex, age, body mass index, and the technical covariates plate layout, RNA Integrity Number, and storage time. 27 In MESA, the models were additionally adjusted for ethnicity. Association statistics from GHS and MESA were pooled by inverse-variance weighting of SEs using METAL (Meta Analyses Helper). 29 In the primary analyses, individuals receiving antihypertensive treatment were not excluded. In a sensitivity analysis, individuals receiving antihypertensive drug treatment were excluded, leading to 941 eligible individuals in GHS, 815 in MESA, 570 in KORA F4, and 602 in SHIP-TREND.
Analyses of Changes in Candidate Transcript Expression Over Time
A detailed description is given in the online-only Data Supplement. Briefly, association analysis between changes of BP traits and changes in candidate transcript expression after 5 years in the GHS was performed using linear regression. Adjustments were performed for sex, age, BP trait at baseline, and body mass index change between baseline and follow-up. Controlling for multiple testing was performed using the Benjamini-Hochberg method, 30 and the significance level was set to 0.05. For changes in gene expression for 5 years in the GHS, results are given as mRNA change per 10-mm Hg increase in BP trait (delta mRNA)±SE.
In the BP-lowering clinical trial, differential expression of candidate transcripts before and after BP-lowering therapy was calculated by linear mixed models adjusted for sex, age, and body mass index. Controlling for multiple testing was performed using the BenjaminiHochberg method, 30 and the significance level was set to 0.05. For differential gene expression in the clinical trial, results are given as percent mRNA change (%mRNA change) after 6 months±SE.
Expression Quantitative Trait Loci (eQTL) Analysis in the GHS
eQTL analyses were performed in 1333 individuals from the GHS with available gene expression and available genome-wide genotyping data. 20 Two approaches were used to identify eQTLs related to BP or CVD: (1) cis-eQTLs were calculated for single nucleotide polymorphisms (SNPs) within ±250 kb around the transcription start site and a minor allele frequency ≥1%, and (2) eQTLs calculated based on published genome-wide association study results of BP-related traits retrieved from the genome-wide association studies catalogue (March 20, 2017).
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Results
BP-Related Gene Expression: Identification and Replication
The study characteristics are outlined in Table S1 . Differential gene expression in relation to BP traits was assessed by a meta-analysis of GHS and MESA monocyte transcriptome data. At a false discovery rate <0.01, 91, 35, and 51, unique transcripts differentially expressed in relation to BP traits were identified (Table S2) .
Validation of monocyte transcript expression findings was performed using whole-blood transcriptome data of 2 independent cohort studies: SHIP-TREND and KORA F4 (Table S3 ). Eight unique transcripts fulfilled criteria for an independent validation at a P<0.05, including 5 for SBP, 6 for DBP, and 3 for pulse pressure (Table 1) , encompassing CRIP1, MYADM, TIPARP, TSC22D3, CEBPA, F12, LMNA, and TPPP3. Of these, CEBPA showed decreased transcripts levels associated with increased BP, whereas the remaining transcript levels were positively associated with BP. Associations between BP traits and expression remained significant after excluding individuals receiving antihypertensive treatment (Table S4 ) and when including only white subjects in MESA (Table S5 ). The BP-related transcripts were expressed at comparable levels in monocytes and whole-blood cells ( Figure S2 ).
Variation of BP Traits Attributable to Candidate Transcripts
To assess the variance in BP levels attributable to gene expression, the R 2 (percentage of phenotypic variance) was calculated (Table S6 ). In aggregate, the genes identified in the transcriptome analyses accounted in total for 2.82% to 11.33% (SBP), 2.11% to 8.31% (DBP), and 1.36% to 4.74% (pulse pressure) of the phenotypic variance of the respective BP traits. These data indicate that a larger proportion of BP variance is attributable to changes in gene expression levels as compared with an explained variance of only 3.5% by common genetic variants.
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Changes in BP and Corresponding Changes in Gene Expression
A direct link between changes in BP and candidate transcript expression in monocytes was assessed in different settings: (1) long-term BP changes for 5 years in the GHS population, and (2) by initiation of BP-lowering therapy for 6 months in a clinical trial.
Long-Term Changes in Transcript Expression in Relation to BP for 5 Years in GHS
In individuals with monocyte transcriptome data available at baseline and 5-year follow-up, a strong association between changes of BP traits and expression levels of CRIP1, MYADM, TIPARP, TSC22D3, CEBPA, LMNA, and TPPP3 was observed (Table 2) . Consistent with the data from the discovery/replication step, a negative association of CEBPA to BP changes was found, whereas the remaining transcripts were positively associated. These associations were independent of antihypertensive drug therapy. CRIP1 transcript levels showed the strongest association with changes in BP traits after 5-year follow-up (% mRNA change per 10 mm Hg SBP: 2.93±0.45; P=2.15×10 −10 ; delta mRNA DBP: 5.19±0.77; P=8.46×10 -11 ; delta mRNA pulse pressure: 2.2±0.62; P=5.0×10 -4 ) . Figure S3a -S3g shows the association between BP changes and respective mRNA level according to categories of BP changes.
Changes in Transcript Expression in Relation to BP by Antihypertensive Medication
BP-lowering medication resulted in a reduction of BP after 6 months ( Figure S4 ). It was expected that this BP reduction lead to a decrease of the expression of transcripts that positively correlated with BP in the discovery phase and vice versa. Accordingly, the reduction of BP associated with a decrease in the expression of 7 of the 8 candidate transcripts (Figure) . The strongest differential expression was found for CRIP1 (% mRNA change: −34.14%±3.55; P=5.6×10 -14 ). Of note, CEBPA (% mRNA change: −51.84%±5.5; P=7.5×10 -16 ) was the only transcript with a divergent expression association pattern, opposite what was expected.
In Table S7 ). All BP modulation strategies confirmed the uniform response of candidate transcripts to BP changes either over time or by BP-lowering medication. The strongest response in all approaches was observed for CRIP1.
Protein Levels of CRIP1 and Incident Cardiovascular Events
For the protein encoded by the most strongly associated transcripts, CRIP1, we investigated the potential to serve as biomarker for future cardiovascular events. We assessed the predictive value of circulating CRIP1 (cystein-rich protein 1) serum levels for the incidence of stroke, heart failure, and coronary artery disease in a population-based sample from the Moli-Sani Study. A significant association was found for incident stroke events (Table 3) , indicating a predictive value of CRIP1 as biomarker for stroke.
Genetic Interplay on BP-Related Transcripts
Because transcript levels might be influenced by genetic variants, eQTL analyses were performed in the GHS monocyte transcriptome data set for SNPs related to BP or CVD traits following 2 approaches ( Figure S5 ). First, regulatory SNPs around the candidate transcripts were examined for CVD-related SNP-trait associations using the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) database. For CRIP1, TPPP3, and LMNA, significant cis-eQTLs (n=25, n=191, and n=30, respectively) were identified. Of these, 2 SNPs around CRIP1 were related to mitral annular calcium (eg, rs10151805; P=4.55×10 -5 ) 32 and 5 SNPs to body mass index (eg, rs1475766; P=6.36×10 -5 ) 29 with P≤10 -4 in the GRASP database (Table S8A ). The aim of the second approach was to investigate whether known BP-associated variants have a regulatory effect on candidate transcript expression. A total of 191 previously published BP-related SNPs were tested for associations with the 8 BP candidate transcripts (Table  S8B) . Two trans-eQTLs were identified (rs653178-T and rs3184504-C) that increased expression of 4 of the candidate genes (CRIP1, MYADM, TPPP2, and TIPARP; Figure  S5 ). These SNPs were located on chromosome 12q24.12 and were in high linkage disequilibrium (pairwise disequilibrium coefficient=0.99; Table S9 ). Both SNPs, rs653178 (intronic to ATXN2) and rs3184504 (nonsynonymous SNP in SH2B3), have already been described as trans-eQTLs in monocytes and whole blood, 15, 19 indicating the importance of these candidate genes for coregulatory mechanisms underlying BP regulation. In our data, CRIP1 expression was most strongly associated with both SNPs (rs653178: mRNA change per T allele±SE: 5.49%±1.05; P=3.59×10 -7 ; rs3184504: mRNA change per C allele±SE: 5.42%±1.06; P=6.53×10 -7 ). The T-allele of rs3184504 was significantly associated with increased DBP (0.8 mm Hg per T-allele; P=0.043) but not to SBP (P=0.342) in the GHS.
Discussion
We demonstrated a direct link between the levels of 8 candidate transcripts and BP at a large scale. Our data show that transcript expression changes account for a large proportion of BP variance, and for the most relevant transcript-CRIP1-we showed a potential clinical application as circulating biomarker.
This study is one of the largest to investigate global gene expression of BP traits at the population level including >4500 individuals, harmonized data sets on monocytic and wholeblood gene expression and BP phenotypes, as well as data on long-term gene expression changes for 5 years from the same individuals.
Several findings from our study contribute to a more detailed understanding to BP genetics. First, compared with genetic variants, gene expression changes are associated with a considerably larger proportion of phenotypic BP variance. The genetic variants identified to date explain 3.5% of the BP variance, 10 whereas the expression of the 8 candidate transcripts in aggregate accounted for up to 11% in our data. Changes in transcript expression, therefore, seem to reflect the biological changes of BP and hypertension in a better way compared with genetic variants.
Second, 8 transcripts were identified that associated with BP changes. These transcripts are not only expressed in blood cells but also in various human cells and tissues as shown by RNA sequencing in the Genotype-Tissue Expression project 32 ( Figure S6 ). Among these genes, CRIP1, MYADM, TIPARP, F12, and TSC22D3 have been previously implicated in hypertension. 15, 19, [33] [34] [35] For the other transcripts, a connection to diseases related to BP, such as obesity and CVD, as well as important roles in the immune system have been described, 36 but the association with BP traits is novel. These findings seem plausible because numerous studies suggest that hypertension represents an inflammatory state and an involvement of the immune system and, in particular, monocytes in the development of hypertension. 3, 37 For instance, selective ablation of lysozyme M-positive myelomonocytic cells attenuated angiotensin II-induced hypertension. 5 Likewise, Itani et al 4 showed that human T cells become activated by hypertensive stimuli, such as angiotensin II. Previous studies identified BP-related signature genes, including MYADM and TIPARP. 15 By using monocytes, an Linear regression models were adjusted for sex, age, and BP trait at baseline and body mass index change between baseline and follow-up. Changes in mRNA expression level (%) are given per 10-mm Hg SBP increase (*), 10-mm Hg DBP increase ( †), and per 10-mm Hg PP increase ( ‡). Significant associations with a false discovery rate ≤0.05 are indicated by §. BP indicates blood pressure; CEBPA, CCAAT/enhancer-binding protein alpha; CRIP1, cysteine-rich protein 1; DBP, diastolic blood pressure; F12, coagulation factor XII; GHS, Gutenberg Health Study; LMNA, lamin A/C; MYADM, myeloid-associated differentiation marker; PP, pulse pressure; SBP, systolic blood pressure; TIPARP, TCDD-inducible poly(ADP-ribose) polymerase; TPPP3, tubulin polymerization-promoting protein family member 3; and TSC22D3, TSC22 domain family member 3.
Figure.
Relationship of blood pressure (BP) reduction and transcript expression by BP-lowering medication for 6 mo (n=406). Transcript expression was measured by quantitative polymerase chain reaction. Linear mixed models adjusted for age, sex, and body mass index were used to calculate differential gene expression. CEBPA indicates CCAAT/enhancer-binding protein alpha; CRIP1, cysteine-rich protein 1; LMNA, lamin A/C; MYADM, myeloid-associated differentiation marker; TIPARP, TCDD-inducible poly(ADP-ribose) polymerase; TPPP3, tubulin polymerization-promoting protein family member 3; and TSC22D3, TSC22 domain family member 3.
important cell type of the innate immune system and effector in inflammation, we identified additional transcripts in relation to BP (CRIP1, TSC22D3, CEBPA, LMNA, TPPP3, and F12). We hypothesize that these genes might contribute to BP regulation and development via their role in the immune system and provide a starting point for further experimental work.
Finally, and clinically most relevant, circulating levels of the protein encoded by the most relevant transcript found-CRIP1-are associated with incident stroke, a sequela of hypertension, implying a potential role of CRIP1 as biomarker.
CRIP1 is a particular interesting candidate transcript for further investigation. In our data, CRIP1 consistently showed the strongest association (1) to BP at the population level, (2) to BP reduction mediated by antihypertensive medication, and (3) to longitudinal changes in BP during a 5-year time frame. The investigation of the genetic interplay by eQTL analyses revealed that the expression of CRIP1 (along with MYADM, TIPARP, and TPPP3) was highly associated with variants in the SH2B3/LNK locus. SH2B3 is a negative regulator of growth factors and cytokine signaling, and previous data have already implicated this locus as a master regulator involved in BP regulation. 14, 19, 38 A Sh2b3 −/− knockout leads to markedly elevated BP in response to low dose of angiotensin II. 16 We speculate that the SH2B3 effect on BP is mediatedat least partly-by CRIP1. CRIP1 belongs to the LIM/double-zinc finger protein family, and a relationship of CRIP1 to hypertension and renal disease has recently been shown. In the renin-expressing juxtaglomerular cells, crucial for BP control, CRIP1 expression was highly increased. 39, 40 CRIP1 is also strongly expressed in immune cells, again indicating a link between CRIP1 and BP regulation via the immune system. Along with the results presented here, these data highlight CRIP1 a promising BP-related candidate transcript for further examinations.
The main strength of this study is the large size of global and harmonized gene expression data that were associated with BP traits at a population level and the analysis of different cell types, including monocytes and whole blood providing a broader view. However, by using these different cell types, we might have missed additional transcripts that would have been discovered when using monocytes only. As we took care to include transcriptomic data derived using the same methodology (Illumina HT-12 Array) and standardized procedures, 27 no additional, independent population-based monocyte transcriptome data set is, to the best of our knowledge, currently available for replication.
As an additional strength, we were able to include data of longitudinal nature (for 5 years and after BP-lowering medication) to provide information on gene expression over time.
A limitation of our work is that, to date, no independent population-based cohort with follow-up expression data is available for replication of our longitudinal data analyses. Furthermore, the highest proportion of explained BP variance by transcripts was observed in the discovery cohorts, and an independent validation in cohorts with available monocytic RNA would be valuable. Moreover, data on the predictive value of circulating CRIP1 levels need to be confirmed in further studies including a broad range of cardiovascular end points. It needs to be considered that CRIP1 levels were determined in a sample of moderate size (n=400), and the coefficient of variation of the ELISA immunoassay was >10%. The lower sample size and the moderate precision of the ELISA assay can cause a bias into the results. We speculate that by increasing the sample size or using a more valid ELISA assay (which is currently not available), the coefficient of variation might improve and increase the precision of the results, also for additional cardiovascular end points. Furthermore, the precise molecular mechanisms underlying the observed associations still require additional experimental follow-up projects.
In conclusion, using large-scale transcriptome data, our analyses highlight 8 transcripts significantly associated with BP. In particular, CRIP1 emerged as an attractive candidate to further elucidate the pathomechanisms of hypertension and to envisage in the long-term therapeutic intervention with respect to BP control.
Perspectives
The results from the present study show that several bloodbased gene transcripts are associated with BP and long-term Cases included subjects with incident stroke, heart failure, and coronary heart disease. Associations between incident events and protein levels were tested by Cox regression adjusted for age, sex, and systolic blood pressure at baseline. CI indicates confidence interval; CRIP1, cystein-rich protein 1 (ng/mL); CRP, C-reactive protein (mg/L); hsTnI, high sensitive troponin I (pg/mL); and NT-proBNP, N-terminal pro-B-type natriuretic peptide (pg/mL).
*The hazard ratio refers to a 1-unit change of a given biomarker.
changes of BP, directly linking gene expression with BP. In addition, circulating levels of the protein encoded by the identified CRIP1 gene strongly associated with incident stroke events. These findings suggest that BP-related transcripts could serve as marker for diagnosis, monitoring, or treatment of hypertension in clinical practice. In particular, CRIP1 might additionally serve as circulating marker for future risk of development of CVD and stroke.
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